Anthropic hopes Powerful AI will “match or exceed the cognitive capabilities of top human experts across scientific disciplines”.

Fresenius and WuXi Biologics will work together to develop up to 37 biosimilar candidates targeting a range of therapeutic areas, giving the German company ample scope to bolster ...

The policy will allow licensed professionals to use certain wellness-focused peptides not approved by the FDA in their compounded medicines.

Xtandi's label as the cancer treatment paradigm shifts towards the use of mutation-specific targeted therapies.

Reaction from the life sciences industry to the Autumn Budget was mixed, with the government opting for a more macro focus on business scaling.

The National Institute for Health and Care Excellence (NICE) has reportedly approved GlaxoSmithKline’s (GSK) Benlysta for the treatment of lupus. Earlier in 2011, NICE rejected Benlysta as it believed ...

Gilead plans to develop HCXT-2001 both as a monotherapy and in combination with its own IBD hopeful, emvistegrast.

Formation Bio has launched the Formation Bio Drug Development Accelerator Fund to broaden the company's clinical-stage medicines portfolio.

Gaelic Labs is eyeing competitive benefits from its 2025 acquisition of fellow Irish beta-lactams manufacturer and further expansion.